{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.62","upperLimit":"45.64","value":"32.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Response was assessed using International Myeloma Working Group (IMWG) Criteria. VGPR is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100 milligram (mg) per 24 hours. The percentage of participants were rounded off to the single decimal point.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or up to 5 years.","id":"OG000","title":"Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg"}],"paramType":"NUMBER","populationDescription":"Response-evaluable population included participants who received at least 1 dose of ixazomib, had measurable disease during the screening period, and have at least 1 postbaseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Participants With Very Good Partial Response (VGPR) or Better (Complete Response + VGPR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}